Follow
Ramanjit Kaur
Ramanjit Kaur
New York University Grossman School of Medicine
Verified email at nyulangone.org
Title
Cited by
Cited by
Year
An ACE2 microbody containing a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2
T Tada, C Fan, JS Chen, R Kaur, KA Stapleford, H Gristick, BM Dcosta, ...
Cell Reports 33 (12), 2020
752020
Chikungunya virus inhibition by peptidomimetic inhibitors targeting virus-specific cysteine protease
H Singh, R Mudgal, M Narwal, R Kaur, VA Singh, A Malik, M Chaudhary, ...
Biochimie 149, 51-61, 2018
582018
Evaluation of antiviral activity of piperazine against Chikungunya virus targeting hydrophobic pocket of alphavirus capsid protein
M Aggarwal, R Kaur, A Saha, R Mudgal, R Yadav, PK Dash, M Parida, ...
Antiviral research 146, 102-111, 2017
532017
The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target
G Rona, A Zeke, B Miwatani-Minter, M de Vries, R Kaur, A Schinlever, ...
Cell Death & Differentiation 29 (2), 285-292, 2022
432022
Glycan-dependent chikungunya viral infection divulged by antiviral activity of NAG specific chi-like lectin
R Kaur, R Mudgal, J Jose, P Kumar, S Tomar
Virology 526, 91-98, 2019
302019
Development of an ELISA assay for screening inhibitors against divalent metal ion dependent alphavirus capping enzyme
R Kaur, R Mudgal, M Narwal, S Tomar
Virus research 256, 209-218, 2018
292018
A soluble ACE2 microbody protein fused to a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2 infection in cell culture
T Tada, C Fan, R Kaur, KA Stapleford, H Gristick, C Nimigean, NR Landau
bioRxiv, 2020.09. 16.300319, 2020
32020
Structure–Function Relationship of Negative-Stranded Viral RNA Polymerases: Prospectives for Antiviral Therapy
S Tomar, R Kaur, VA Singh
Viral Polymerases, 43-67, 2019
32019
Restriction of SARS-CoV-2 replication by receptor transporter protein 4 (RTP4)
R Kaur, T Tada, NR Landau
Mbio 14 (4), e01090-23, 2023
22023
The system can't perform the operation now. Try again later.
Articles 1–9